On the heels of the final decision from CMS regarding coverage for amyloid imaging, Peter Herscovitch, MD, SNMMI 2013-2014 president elect, discussed the potential impact of the new climate of coverage in an exclusive interview with Molecular Imaging.

The National Football League (NFL) attempted to downplay the risks of playing football and tried to influence concussion research, according to bombshell allegations in a new book, “League of Denial: The NFL, Concussions and the Battle for Truth.”

Multiparametric MRI has high diagnostic ability for anterior prostate cancer and was able to identify lesions missed by a standard transrectal 12-core prostate biopsy, according to a study published in the September issue of The Journal of Urology.

Current literature on amyloid-beta PET imaging for Alzheimer’s disease (AD) is insufficient to provide conclusive evidence that the test leads to better clinical outcomes, according to a review summarized online Sept. 30 in JAMA Internal Medicine.

Sofie Biosciences, an emerging in vivo imaging diagnostics company focused on PET probes, scanners and chemistry systems,announced today that the National Institute of Health has awarded the company a grant under the Small Business Innovation Research (SBIR) program.

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States (U.S.) Food and Drug Administration (FDA) granted accelerated approval of a Perjeta (pertuzumab) regimen for neoadjuvant treatment (use before surgery) in people with high-risk, HER2-positive early stage breast cancer. This approval is based primarily on data from a Phase II study showing that nearly 40 percent of people receiving the combination of Perjeta, Herceptin (trastuzumab) and docetaxel chemotherapy had no evidence of tumour tissue detectable at the time of surgery (known as a pathological complete response, or pCR). The Perjeta regimen is the first neoadjuvant breast cancer treatment approved by the FDA and also the first to be approved based on pCR data.

A tau-imaging agent has moved ahead of the pack to pick up strong signals of tau aggregates in the brain in patterns consistent with Alzheimer’s disease (AD), according a study published Sept. 18 in Neuron.

Soldiers suffering from traumatic brain injury (TBI) caused by an explosive blast had a higher rate of anterior pituitary dysfunction than people who sustained a non-blast TBI, suggesting pituitary dysfunction is a particular problem after blast exposure, according to a study published online Sept. 24 in Annals of Neurology.